drugset / Trial / NCT04303377

Summary

This is a prospective, multi-centre, open label, randomised study of Phase II that enrolls patients hospitalized with a diagnosis of ST-elevation myocardial infarction (STEMI), comparing Evolocumab versus Standard of Care.

Timeline

Start
2019-11-18
Primary completion
2020-01-02
Completion
2020-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Evolocumab Monoclonal antibody 140 mg